Sarepta Therapeutics Named One of The Boston Globe’s Top Places to Work 2020
November 20 2020 - 08:30AM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision
genetic medicine for rare diseases, announced today that it has
been named one of The Boston Globe’s Top Places to Work in
2020 in the large company category.
The Boston Globe’s 2020 list recognizes 150
companies and organizations in Massachusetts based on surveys
completed by their employees about the workplace, including 40 in
the large company category. The survey measured opinions about
company direction, execution, connection, management, work, pay and
benefits, and engagement. Companies also provided supplemental
information about responses to the global pandemic and changes
implemented in how teams work.
“This recognition reflects the quality of the
Sarepta employees, who together have built a positive culture,
navigated a challenging environment this year and, both at
facilities and from home, remained focused on our daily race to
save lives stolen or impacted by rare disease,” said Doug Ingram,
president and CEO, Sarepta. “It is a testament to the resilience,
tenacity and commitment of those who work at Sarepta.”
Sarepta is committed to engineering precision
genetic medicine to reclaim futures otherwise impacted or cut short
by ushering in a new era of drug development, with the goal of
shortening the time from lab to patient. The Company is building
among the world’s largest gene therapy manufacturing capacity, and
rethinking access and reimbursement models for revolutionary new
treatments. Sarepta’s purpose-driven culture, where patient-focus
is central to the values that shape how work is done, was
resoundingly echoed by its people as a key attribute that
contributed to its top ranking. Additionally, Sarepta fosters an
environment that encourages its people to bring their whole selves
to work and share ideas that support the entire workforce and the
patient community it serves.
As the Company adjusted during the pandemic,
several initiatives and new benefits were implemented as a result
of employee feedback:
- Employees
rethought how clinical trials were conducted and how to make it
easier for patients to participate.
- The Company
launched multiple caregiving benefits for employees managing
dependent care, including tutoring support and an employee-led
babysitting exchange program to help parents manage working from
home and address childcare needs.
- Virtual health
and wellness seminars focused on coping under chronic stress and
during transitions, and employees received virtual care
packages.
- Employee
Resource Groups addressed diversity, equity and inclusion by
bringing together diverse groups to support organization and
personal growth.
- Employees
remain connected to the communities in which they work and live
through volunteer opportunities and Company sponsorship of
non-profit organizations.
At Sarepta, a vision for the possibilities of
pioneering science to redefine the future of medicine, and advance
treatment options for patients, is shared by all. Individuals who
are inspired by the opportunity to toss aside convention and break
down barriers to radically change the future of medicine are
encouraged to explore employment opportunities at
www.sarepta.com.
About Sarepta TherapeuticsAt
Sarepta, we are leading a revolution in precision genetic medicine
and every day is an opportunity to change the lives of people
living with rare disease. The Company has built an impressive
position in Duchenne muscular dystrophy (DMD) and in gene therapies
for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis
type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related
disorders, with more than 40 programs in various stages of
development. The Company’s programs and research focus span several
therapeutic modalities, including RNA, gene therapy and gene
editing. For more information, please
visit www.sarepta.com or follow us
on Twitter, LinkedIn, Instagram and Facebook.
Source: Sarepta Therapeutics, Inc.
Media and
Investors:Sarepta Therapeutics, Inc.
Investors: Ian Estepan, 617-274-4052, iestepan@sarepta.com Media:
Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Mar 2023 to Mar 2024